Jean-Jacques Kiladjian
INSERM Pôle Recherche Clinique · FIM · (France) Clinical Investigations Center, Saint-Louis Hospital, Paris, France
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Jean-Jacques Kiladjian as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 00:33 UTC. Open this list on ClinicalTrials.gov
- Ph1NCT06024421 · Evaluation of Tolerance and Pharmacokinetic Profile of High Doses of Favipiravir in Healthy VolunteersInstitut National de la Santé Et de la Recherche Médicale, France · recruiting · Infectious Disease, Pharmacology · study director
- N/ANCT04416438 · COVID-19 Epidemic and Patients With Myeloproliferative NeoplasiasFrench Innovative Leukemia Organisation · completed · Myeloproliferative Neoplasm, COVID-19 Infection · principal investigator
- Ph3NCT04116502 · MITHRIDATE: Ruxolitinib Versus Hydroxycarbamide or Interferon as First Line Therapy in High Risk Polycythemia VeraUniversity of Birmingham · recruiting · Polycythemia Vera · principal investigator
- Ph1/Ph2NCT02742324 · Trial Ruxolitinib and Peg-interferon Alpha-2a Combination in Patients With Primary Myelofibrosis RUXOPegFrench Innovative Leukemia Organisation · completed · Myelofibrosis
- Ph3NCT01259856 · Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET)Ronald Hoffman · completed · High Risk Polycythemia Vera, High Risk Essential Thrombocythemia · study chair
- Ph2NCT00241241 · Efficacy and Safety of Pegylated Interferon Alfa in Polycythemia VeraPV-Nord · completed · Polycythemia Vera · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 00:33 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Project 3: Development of Strategies to Deplete Myelofibrosis Stem CellsP01CA108671 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Ronald Hoffman · fiscal years 2006 to 2026Named on NCT01259856
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 00:33 UTC. The ranking covers the 200 most relevant of 67 PubMed records, and a shared surname and initials can bring in a namesake. All 67 on PubMed
- 1,537 citationsRCR 38.1
- Ruxolitinib versus standard therapy for the treatment of polycythemia vera.N Engl J Med · 2015680 citationsRCR 21.0
- 480 citationsRCR 10.6
- Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis.Leukemia · 2016415 citationsRCR 14.1
- 363 citationsRCR 10.6
- Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria.N Engl J Med · 2021351 citationsRCR 21.9
- SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor-Naïve Patients With Myelofibrosis.J Clin Oncol · 2017336 citationsRCR 10.1
- Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study.Lancet Haematol · 2020319 citationsRCR 16.5
- Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study.Lancet Haematol · 2017294 citationsRCR 9.3
- Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial.Lancet Haematol · 2017289 citationsRCR 8.8